|Bid||116.18 x 1300|
|Ask||117.18 x 800|
|Day's Range||115.36 - 116.88|
|52 Week Range||79.65 - 127.68|
|Beta (5Y Monthly)||1.43|
|PE Ratio (TTM)||39.37|
|Earnings Date||Aug 30, 2021 - Sep 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||135.20|
According to Quest Diagnostics (DGX), Q2 is the first quarter since 2019 in which it has registered organic base testing revenue growth.
Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities. The plant is currently filling vials of COVID-19 vaccines for AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ). The company plans to install two 2,000-liter single-use bioreactors at the Anagni plant and the infrastructure required for another six 2,000-liter single-use bioreactors. The initial expans
Catalent expects the expansion will allow it by April 2023 to be able to make the drug substance for complicated biologic drugs, including COVID-19 vaccines or therapies like monoclonal antibodies. "In Europe there is a shortage of capacity of bioreactors for biologic (drugs)," Mario Gargiulo, Catalent's Region President of Biologics in Europe said in an interview. The company plans to install two 2,000-liter single-use bioreactors at the Anagni plant, as well as the infrastructure required for another six 2,000-liter single-use bioreactors.